Graham M Snyder1, Priti R Patel2, Alexander J Kallen2, James A Strom3, J Kevin Tucker4, Erika M C D'Agata5. 1. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Electronic address: gsnyder@bidmc.harvard.edu. 2. Centers for Disease Control and Prevention, Atlanta, GA. 3. St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA. 4. Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 5. Rhode Island Hospital, Brown University School of Medicine, Providence, RI.
Abstract
BACKGROUND: Antimicrobial use is common among patients receiving chronic hemodialysis (CHD) and may represent an important antimicrobial stewardship opportunity. The objective of this study is to characterize CHD patients at increased risk of receiving antimicrobials, including not indicated antimicrobials. METHODS: We conducted a prospective cohort study over a 12-month period among patients receiving CHD in 2 outpatient dialysis units. Each parenteral antimicrobial dose administered was characterized as indicated or not indicated based on national guidelines. Patient factors associated with receipt of antimicrobials and receipt of ≥1 inappropriate antimicrobial dose were analyzed. RESULTS: A total of 89 of 278 CHD patients (32%) received ≥1 antimicrobial doses and 52 (58%) received ≥1 inappropriately indicated dose. Patients with tunneled catheter access, a history of colonization or infection with a multidrug-resistant organism, and receiving CHD sessions during daytime shifts were more likely to receive antimicrobials (odds ratio [OR], 5.16; 95% confidence interval [CI], 2.72-9.80; OR, 5.43; 95% CI, 1.84-16.06; OR, 4.59; 95% CI, 1.20-17.52, respectively). Patients with tunneled catheter access, receiving CHD at dialysis unit B, and with a longer duration of CHD prior to enrollment were at higher risk of receiving an inappropriately indicated antimicrobial dose (incidence rate ratio, 2.23; 95% CI, 1.16-4.29; incidence rate ratio, 2.67; 95% CI, 1.34-5.35; incidence rate ratio, 1.11; 95% CI, 1.01-1.23, respectively). CONCLUSIONS: This study of all types of antimicrobials administered in 2 outpatient dialysis units identified several important factors to consider when developing antimicrobial stewardship programs in this health care setting.
BACKGROUND: Antimicrobial use is common among patients receiving chronic hemodialysis (CHD) and may represent an important antimicrobial stewardship opportunity. The objective of this study is to characterize CHD patients at increased risk of receiving antimicrobials, including not indicated antimicrobials. METHODS: We conducted a prospective cohort study over a 12-month period among patients receiving CHD in 2 outpatient dialysis units. Each parenteral antimicrobial dose administered was characterized as indicated or not indicated based on national guidelines. Patient factors associated with receipt of antimicrobials and receipt of ≥1 inappropriate antimicrobial dose were analyzed. RESULTS: A total of 89 of 278 CHD patients (32%) received ≥1 antimicrobial doses and 52 (58%) received ≥1 inappropriately indicated dose. Patients with tunneled catheter access, a history of colonization or infection with a multidrug-resistant organism, and receiving CHD sessions during daytime shifts were more likely to receive antimicrobials (odds ratio [OR], 5.16; 95% confidence interval [CI], 2.72-9.80; OR, 5.43; 95% CI, 1.84-16.06; OR, 4.59; 95% CI, 1.20-17.52, respectively). Patients with tunneled catheter access, receiving CHD at dialysis unit B, and with a longer duration of CHD prior to enrollment were at higher risk of receiving an inappropriately indicated antimicrobial dose (incidence rate ratio, 2.23; 95% CI, 1.16-4.29; incidence rate ratio, 2.67; 95% CI, 1.34-5.35; incidence rate ratio, 1.11; 95% CI, 1.01-1.23, respectively). CONCLUSIONS: This study of all types of antimicrobials administered in 2 outpatient dialysis units identified several important factors to consider when developing antimicrobial stewardship programs in this health care setting.
Authors: Timothy H Dellit; Robert C Owens; John E McGowan; Dale N Gerding; Robert A Weinstein; John P Burke; W Charles Huskins; David L Paterson; Neil O Fishman; Christopher F Carpenter; P J Brennan; Marianne Billeter; Thomas M Hooton Journal: Clin Infect Dis Date: 2006-12-13 Impact factor: 9.079
Authors: L Galoisy-Guibal; J L Soubirou; G Desjeux; J Y Dusseau; O Eve; J Escarment; R Ecochard Journal: Infect Control Hosp Epidemiol Date: 2006-10-04 Impact factor: 3.254
Authors: David N Schwartz; Ulysses S Wu; Rosie D Lyles; Yingxu Xiang; Piotr Kieszkowski; Bala Hota; Robert A Weinstein Journal: Infect Control Hosp Epidemiol Date: 2009-02 Impact factor: 3.254
Authors: Michael Allon; John Daugirdas; Thomas A Depner; Tom Greene; Daniel Ornt; Steve J Schwab Journal: Am J Kidney Dis Date: 2006-03 Impact factor: 8.860
Authors: E P Dellinger; P A Gross; T L Barrett; P J Krause; W J Martone; J E McGowan; R L Sweet; R P Wenzel Journal: Clin Infect Dis Date: 1994-03 Impact factor: 9.079
Authors: Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett Journal: Surg Infect (Larchmt) Date: 2010-02 Impact factor: 2.150
Authors: Brandon Eilertson; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; Jack DeHovitz; Barry Kreiswirth; David van Duin Journal: Open Forum Infect Dis Date: 2017-10-06 Impact factor: 3.835